Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells

Um, Soyoun; Ha, Jihun; Choi, Soo Jin; Oh, Wonil; Jin, Hye Jin

doi:10.4252/wjsc.v12.i12.1511

Cited by 27 publications

(14 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human umbilical cord mesenchymal stem cells are mainly derived from umbilical cord blood, Wharton’s jelly, blood vessels and their surrounding tissues [ 91 ]. An early study showed that many pluripotent MSCs could be isolated from UC samples, of which the cells obtained from umbilical cord blood were the most abundant, and UC-MSCs were more abundant in preterm cord blood than in term blood [ 92 ].…”

Section: Mscs-based Treatment Of Opmentioning

confidence: 99%

The therapeutic potential of mesenchymal stem cells in treating osteoporosis

et al. 2021

View full text Add to dashboard Cite

Osteoporosis (OP), a common systemic metabolic bone disease, is characterized by low bone mass, increasing bone fragility and a high risk of fracture. At present, the clinical treatment of OP mainly involves anti-bone resorption drugs and anabolic agents for bone, but their long-term use can cause serious side effects. The development of stem cell therapy and regenerative medicine has provided a new approach to the clinical treatment of various diseases, even with a hope for cure. Recently, the therapeutic advantages of the therapy have been shown for a variety of orthopedic diseases. However, these stem cell-based researches are currently limited to animal models; the uncertainty regarding the post-transplantation fate of stem cells and their safety in recipients has largely restricted the development of human clinical trials. Nevertheless, the feasibility of mesenchymal stem cells to treat osteoporotic mice has drawn a growing amount of intriguing attention from clinicians to its potential of applying the stem cell-based therapy as a new therapeutic approach to OP in the future clinic. In the current review, therefore, we explored the potential use of mesenchymal stem cells in human OP treatment.

show abstract

Section: Mscs-based Treatment Of Opmentioning

confidence: 99%

The therapeutic potential of mesenchymal stem cells in treating osteoporosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Delivery of MSC-Exos in stroke models leads to long-term neuroprotection, improved neurogenesis and neurovascular remodeling, as well as enhanced behavioral and neurological performances in motor function, coordination, sensorimotor, and spatial learning [136,317,324,[326][327][328][329][330]. Varied contents of exosomes have been shown to aid recuperation, from growth factors such as VEGF to microRNAs [46,331]. Zheng et al identified that miR-25 in MSC-Exos improved cell viability following stroke through modulation of BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, while in a model of middle cerebral artery occlusion, miR-133b secreted from MSCs led to improved neurogenesis and stroke recovery [46,310,311,330].…”

Section: Brain Injurymentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine

Hade

Suire

Suo

2021

Cells

231

154

View full text Add to dashboard Cite

Exosomes are a type of extracellular vesicles, produced within multivesicular bodies, that are then released into the extracellular space through a merging of the multivesicular body with the plasma membrane. These vesicles are secreted by almost all cell types to aid in a vast array of cellular functions, including intercellular communication, cell differentiation and proliferation, angiogenesis, stress response, and immune signaling. This ability to contribute to several distinct processes is due to the complexity of exosomes, as they carry a multitude of signaling moieties, including proteins, lipids, cell surface receptors, enzymes, cytokines, transcription factors, and nucleic acids. The favorable biological properties of exosomes including biocompatibility, stability, low toxicity, and proficient exchange of molecular cargos make exosomes prime candidates for tissue engineering and regenerative medicine. Exploring the functions and molecular payloads of exosomes can facilitate tissue regeneration therapies and provide mechanistic insight into paracrine modulation of cellular activities. In this review, we summarize the current knowledge of exosome biogenesis, composition, and isolation methods. We also discuss emerging healing properties of exosomes and exosomal cargos, such as microRNAs, in brain injuries, cardiovascular disease, and COVID-19 amongst others. Overall, this review highlights the burgeoning roles and potential applications of exosomes in regenerative medicine.

show abstract

“…At present, the role of MSCs in the progression of glioma is still controversial. Some scholars believe that MSCs can promote the progression of glioma, while others believe that they exert an inhibitory effect [ 16 ]. In our previous study, with the help of orthotopic models of GSC-MSC interactions, we showed that the MSCs that migrated into the glioma environment were malignantly transformed by GSCs, which might be related to the malignant progression of gliomas [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

HOTAIRM1 Maintained the Malignant Phenotype of tMSCs Transformed by GSCs via E2F7 by Binding to FUS

Liu

Zhou

Dong

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. Mesenchymal stromal/stem cells (MSCs) are an important part of the glioma microenvironment and are involved in the malignant progression of glioma. In our previous study, we showed that MSCs can be induced to a malignant phenotype (tMSCs) by glioma stem cells (GSCs) in the microenvironment. However, the potential mechanism by which tMSCs maintain their malignant phenotype after malignant transformation has not been fully clarified. Methods. The expression of HOTAIRM1, FUS, and E2F7 was detected by qRT-PCR. Clone formation, EdU, and Transwell assay were used to explore the role of HOTAIRM1, FUS, and E2F7 on the proliferation, migration, and invasion of tMSCs. Bioinformatics analysis and RNA immunoprecipitation were used to explore the relation among HOTAIRM1, FUS, and E2F7. Results. HOTAIRM1 was upregulated in tMSCs compared with MSCs. Loss- and gain-of-function assays showed that HOTAIRM1 promoted the proliferation, migration, and invasion of tMSCs. qRT-PCR and functional assays revealed that E2F7 might be the downstream target of HOTAIRM1. A further study of the mechanism showed that HOTAIRM1 could bind to FUS, an RNA-binding protein (RBP), and thus regulate E2F7, which could promote the malignant phenotype of tMSCs. Conclusion. Our study revealed that the HOTAIRM1/FUS/E2F7 axis is involved in the malignant progression of tMSCs transformed by GSCs in the glioma microenvironment and may function as a novel target for glioma therapy.

show abstract

Prospects for the therapeutic development of umbilical cord blood-derived mesenchymal stem cells

Cited by 27 publications

References 146 publications

The therapeutic potential of mesenchymal stem cells in treating osteoporosis

The therapeutic potential of mesenchymal stem cells in treating osteoporosis

Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine

HOTAIRM1 Maintained the Malignant Phenotype of tMSCs Transformed by GSCs via E2F7 by Binding to FUS

Contact Info

Product

Resources

About